DE69520844D1 - Verfahren zur Verhinderung der Zersetzung des Proteins C - Google Patents

Verfahren zur Verhinderung der Zersetzung des Proteins C

Info

Publication number
DE69520844D1
DE69520844D1 DE69520844T DE69520844T DE69520844D1 DE 69520844 D1 DE69520844 D1 DE 69520844D1 DE 69520844 T DE69520844 T DE 69520844T DE 69520844 T DE69520844 T DE 69520844T DE 69520844 D1 DE69520844 D1 DE 69520844D1
Authority
DE
Germany
Prior art keywords
apc
protein
decomposition
preventing
autodegradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69520844T
Other languages
English (en)
Other versions
DE69520844T2 (de
Inventor
Jr Walter Francis Prouty
Josephine Secnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69520844(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69520844D1 publication Critical patent/DE69520844D1/de
Publication of DE69520844T2 publication Critical patent/DE69520844T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69520844T 1994-01-05 1995-01-04 Verfahren zur Verhinderung der Zersetzung des Proteins C Expired - Lifetime DE69520844T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05

Publications (2)

Publication Number Publication Date
DE69520844D1 true DE69520844D1 (de) 2001-06-13
DE69520844T2 DE69520844T2 (de) 2001-11-08

Family

ID=22650141

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002199053 Active DE10299053I2 (de) 1994-01-05 1995-01-04 Verfahren zur Verhinderung der Zersetzung des Proteins C.
DE69520844T Expired - Lifetime DE69520844T2 (de) 1994-01-05 1995-01-04 Verfahren zur Verhinderung der Zersetzung des Proteins C

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2002199053 Active DE10299053I2 (de) 1994-01-05 1995-01-04 Verfahren zur Verhinderung der Zersetzung des Proteins C.

Country Status (29)

Country Link
EP (2) EP1087011A3 (de)
JP (1) JP3778588B2 (de)
KR (1) KR950032287A (de)
CN (1) CN1109891A (de)
AT (1) ATE201045T1 (de)
AU (1) AU1003195A (de)
BR (1) BR9500017A (de)
CA (1) CA2139468C (de)
CO (1) CO4600680A1 (de)
CZ (1) CZ1395A3 (de)
DE (2) DE10299053I2 (de)
DK (1) DK0662513T3 (de)
ES (1) ES2156190T3 (de)
FI (1) FI115635B (de)
GR (1) GR3036277T3 (de)
HU (1) HUT70465A (de)
IL (1) IL112236A (de)
LU (2) LU90993I2 (de)
NL (1) NL300108I2 (de)
NO (2) NO320157B1 (de)
NZ (1) NZ270271A (de)
PE (1) PE43995A1 (de)
PL (1) PL180703B1 (de)
PT (1) PT662513E (de)
RU (1) RU2167936C2 (de)
SI (1) SI0662513T1 (de)
UA (1) UA39178C2 (de)
YU (1) YU295A (de)
ZA (1) ZA9514B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HU224826B1 (en) * 1997-04-28 2006-02-28 Lilly Co Eli Activated protein c formulations
EP1557463A1 (de) * 1997-04-28 2005-07-27 Eli Lilly & Company Verbesserte Methoden zur Verarbeitung von aktiviertem Protein C
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c

Also Published As

Publication number Publication date
EP0662513B1 (de) 2001-05-09
CA2139468C (en) 2007-08-21
UA39178C2 (uk) 2001-06-15
DE69520844T2 (de) 2001-11-08
PL306671A1 (en) 1995-07-10
NO950018L (no) 1995-07-06
NL300108I2 (nl) 2003-06-02
CN1109891A (zh) 1995-10-11
IL112236A (en) 1999-12-31
EP1087011A2 (de) 2001-03-28
IL112236A0 (en) 1995-03-30
EP0662513A1 (de) 1995-07-12
GR3036277T3 (en) 2001-10-31
FI115635B (fi) 2005-06-15
FI950044A (fi) 1995-07-06
HU9500021D0 (en) 1995-03-28
SI0662513T1 (en) 2001-10-31
BR9500017A (pt) 1995-10-03
NO2006006I1 (no) 2006-05-15
KR950032287A (ko) 1995-12-20
CA2139468A1 (en) 1995-07-06
NZ270271A (en) 1996-07-26
CZ1395A3 (en) 1995-07-12
AU1003195A (en) 1995-07-13
NO950018D0 (no) 1995-01-03
PT662513E (pt) 2001-08-30
LU90993I2 (fr) 2003-02-18
ATE201045T1 (de) 2001-05-15
PE43995A1 (es) 1995-12-15
CO4600680A1 (es) 1998-05-08
DE10299053I2 (de) 2004-04-01
YU295A (sh) 1997-09-30
EP1087011A3 (de) 2002-02-06
LU90992I2 (fr) 2003-02-18
DK0662513T3 (da) 2001-05-28
JP3778588B2 (ja) 2006-05-24
RU2167936C2 (ru) 2001-05-27
ZA9514B (en) 1996-07-03
RU95100178A (ru) 1997-03-27
NO320157B1 (no) 2005-11-07
DE10299053I1 (de) 2003-05-22
HUT70465A (en) 1995-10-30
FI950044A0 (fi) 1995-01-04
NL300108I1 (nl) 2003-02-03
ES2156190T3 (es) 2001-06-16
PL180703B1 (pl) 2001-03-30
JPH07206704A (ja) 1995-08-08

Similar Documents

Publication Publication Date Title
ATE191513T1 (de) Verfahren zur amplifikation von nukleinsäuren
DK83093D0 (da) Fremgangsmaade
DE69631996D1 (de) Verfahren zur Herstellung von acylierten Proteinpuder
ATE515578T1 (de) Verfahren und vorrichtung zur nukleinsäurereinigung
NO2006006I1 (no) Aktivert protein C
ATE96805T1 (de) Verfahren zur rueckgewinnung rekombinanter proteine.
DE59108583D1 (de) Verfahren zur reaktivierung von denaturiertem protein
GR1001480B (el) Ενζυμικά σκευάσματα περιέχοντα παπαϊνη ή χυμο?ρυψίνη και μέ?οδοι μόνιμης ενζυμικής αποτρίχωσης.
ATE215784T1 (de) Verfahren zur herstellung eines kappa-casein- glykomakropeptides oder eines abkoemmlings davon
ATE220678T1 (de) Verfahren zur gewinnung von hämin aus schlachtblut
DE69715053T2 (de) Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten
DE60023491D1 (de) Verfahren zur Herstellung eines hochgereinigten pflanzlichen Proteins mit niedriger Ribonukleinsäure- Konzentration
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี